Schedule 4

Canopy Growth Reports Third Quarter Fiscal Year 2024 Financial Results; Achieves Third Quarter of Sequential Revenue Growth across Canada Cannabis Businesses and a Record Quarter for Medical Sales

Retrieved on: 
Friday, February 9, 2024

See "Non-GAAP Measures" and Schedule 4 for a reconciliation of net revenue to adjusted gross margin.

Key Points: 
  • See "Non-GAAP Measures" and Schedule 4 for a reconciliation of net revenue to adjusted gross margin.
  • See "Non-GAAP Measures" and Schedule 6 for a reconciliation of net cash used in operating activities to free cash flow.
  • 6 In Q3 FY2024, we are reporting our financial results for the following four reportable segments: (i) Canada cannabis; (ii) rest-of-world cannabis; (iii) Storz & Bickel; and (iv)
    This Works.
  • Information regarding segment net revenue and segment gross margin for the comparative periods has been restated to reflect the aforementioned change in reportable segments.

EQS-News: Mobile TeleSystems PJSC: IMPORTANT NOTICE TO NOTEHOLDERS

Retrieved on: 
Sunday, November 27, 2022

THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF HOLDERS.

Key Points: 
  • THIS NOTICE IS IMPORTANT AND REQUIRES THE IMMEDIATE ATTENTION OF HOLDERS.
  • THIS NOTICE CONTAINS IMPORTANT INFORMATION THAT IS OF INTEREST TO THE REGISTERED AND BENEFICIAL OWNERS OF THE NOTES.
  • IF APPLICABLE, ALL DEPOSITORIES, CUSTODIANS AND OTHER INTERMEDIARIES RECEIVING THIS NOTICE ARE REQUIRED TO EXPEDITE TRANSMISSION HEREOF TO BENEFICIAL OWNERS OF THE NOTES IN A TIMELY MANNER.
  • The distribution of this notice and the Consent Solicitation Memorandum to which it relates in certain jurisdictions may be restricted by law.

EQS-News: Mobile TeleSystems PJSC: NOTICE OF MEETING

Retrieved on: 
Sunday, November 27, 2022

MTS PJSC (the "Company") hereby requests that the holders of U.S.$500,000,000 5 per cent.

Key Points: 
  • MTS PJSC (the "Company") hereby requests that the holders of U.S.$500,000,000 5 per cent.
  • Terms not otherwise defined in this Extraordinary Resolution shall have the meaning ascribed thereto in the Consent Solicitation Memorandum dated 21 November 2022.
  • 21.11.2022 MSK Dissemination of a Corporate News, transmitted by EQS News - a company of EQS Group AG.
  • The EquityStory.RS, LLC Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

NETSOL Technologies Reports Fiscal First Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 10, 2022

Total net revenues for the first quarter of fiscal 2023 were $12.7 million, compared with $13.4 million in the prior year period.

Key Points: 
  • Total net revenues for the first quarter of fiscal 2023 were $12.7 million, compared with $13.4 million in the prior year period.
  • Gross profit for the first quarter of fiscal 2023 decreased to $4.3 million (or 33.5% of net revenues), compared to $5.4 million (or 40.6% of net revenues) in the first quarter of fiscal 2022.
  • Operating expenses for the first quarter of fiscal 2023 were $6.1 million (or 48.4% of sales) compared to $6.1 million (or 45.3% of sales) for the first quarter of fiscal 2022.
  • On a constant currency basis, GAAP net loss attributable to NETSOL for the first quarter of fiscal 2023 totaled $(912,000) or $(0.08) per diluted share.

NETSOL Technologies Reports Fiscal First Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 11, 2021

Total net revenues for the first quarter of fiscal 2022 were $13.4 million, compared with $12.6 million in the prior year period.

Key Points: 
  • Total net revenues for the first quarter of fiscal 2022 were $13.4 million, compared with $12.6 million in the prior year period.
  • Gross profit for the first quarter of fiscal 2022 decreased 14.7% to $5.4 million (or 40.6% of net revenues), compared to $6.4 million (or 50.5% of net revenues) in the first quarter of fiscal 2021.
  • Operating expenses for the first quarter of fiscal 2022 increased 13.8% to $6.1 million (or 45.3% of sales) from $5.3 million (or 42.3% of sales) for the first quarter of fiscal 2021.
  • GAAP net income attributable to NETSOL for the first quarter of fiscal 2022 totaled $188,000 or $0.02 per diluted share, compared with GAAP net income of $718,000 or $0.06 per diluted share in the first quarter of fiscal 2021.

KemPharm Announces Serdexmethylphenidate (SDX) Has Been Classified as a Schedule IV Controlled Substance by the DEA

Retrieved on: 
Friday, May 7, 2021

AZSTARYS is classified as a Schedule II controlled substance as it includes a 70:30 mixture of SDX (Schedule IV) and d-MPH (Schedule II), respectively.\nAccording to the \xe2\x80\x9cSchedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV,\xe2\x80\x9d which has been published in the Federal Register (federalregister.gov/d/2021-09738), the DEA concluded that SDX meets the 21 U.S.C.

Key Points: 
  • AZSTARYS is classified as a Schedule II controlled substance as it includes a 70:30 mixture of SDX (Schedule IV) and d-MPH (Schedule II), respectively.\nAccording to the \xe2\x80\x9cSchedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV,\xe2\x80\x9d which has been published in the Federal Register (federalregister.gov/d/2021-09738), the DEA concluded that SDX meets the 21 U.S.C.
  • 812(b)(4) criteria for placement in schedule IV of the Controlled Substances Act (CSA).
  • \xe2\x80\x9cKP879, which is intended for the treatment of stimulant use disorder, is based on SDX as the sole API.
  • KemPharm\xe2\x80\x99s lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).